section name header

Basics

Punit Agrawal, DO


BASICS

DESCRIPTION

Involuntary sustained or repetitive posturing/twisting movements in the face, neck, trunk, or limbs caused by abnormal activity in both agonistic and antagonistic muscles.

EPIDEMIOLOGY

Incidence and prevalence has been estimated for primary dystonia.

Incidence

2 per million for generalized dystonia and 24 per million for focal dystonia (1).

Prevalence

3.4 per 100,000 for generalized dystonia and 30 per 100,000 for focal dystonia.

RISK FACTORS

Genetics

Several genes have been identified classified to primary dystonia, dystonia plus syndromes, and paroxysmal disorders. Some of the better recognized ones are discussed here.

PATHOPHYSIOLOGY

Exact pathophysiology is not known. Dysfunction in the sensory–motor portion of the basal ganglia or thalamus may lead to impaired inhibition of thalamic–cortical activity, which results in increased unwanted movements (2). This has been demonstrated with dystonia arising after structural lesions in these brain areas. Drugs and toxins that disrupt proper function of the basal ganglia can predispose to dystonia. Dopamine is implicated in some forms of dystonia supported by therapeutic effects in dopa-responsive dystonia, and also tardive dystonia seen with use of dopamine-blocking agents.

ETIOLOGY

Divided into 3 categories, but in many cases the cause may be difficult to determine.

COMMONLY ASSOCIATED CONDITIONS

Diagnosis

DIAGNOSIS

HISTORY

Classification

PHYSICAL EXAM

DIAGNOSTIC TESTS AND INTERPRETATION

Lab

Initial Lab Tests

Follow-Up & Special Considerations

If dystonia occurs in absence of other abnormal symptoms with onset before the age of 26 years, then consider commercially available DYT1 genetic testing, especially if positive family history of dystonia (2)[C].

Imaging

MRI/CT if hemidystonia or secondary dystonia to assess for CNS structural lesions (3)[C].

Diagnostic Procedures/Other

DIFFERENTIAL DIAGNOSIS

Treatment

TREATMENT

MEDICATION

First Line

Second Line

ADDITIONAL TREATMENT

Issues for Referral

Additional Therapies

Physical, occupational, or speech therapy

COMPLEMENTARY AND ALTERNATIVE THERAPIES

Surgical considerations for medication and botulinum toxin therapy refractory dystonia:

Ongoing Care

ONGOING-CARE

FOLLOW-UP RECOMMENDATIONS

Botulinum toxin therapy requires repeat treatment, but no sooner than 3 months apart. Also may require more frequent visits to observe for effects.

PATIENT EDUCATION

PROGNOSIS

Chronic disorder that often requires ongoing symptomatic treatment. Focal dystonia may be self-limiting with plateau in progression. Generalized dystonia may spread and eventually cause severe disability.

COMPLICATIONS

Contractures may develop with sustained postures. Generalized dystonia may affect swallowing and breathing as well.

Codes

CODES

ICD9

Clinical Pearls

References

  1. Defazio G. The epidemiology of primary dystonia: current evidence and perspectives. Eur J Neurol 2010;17(suppl):9–14.
  2. Tarsy D, Simons D. Dystonia. N Engl J Med 2006;335:818–829.
  3. Albanese A, Barnes MP, Bhatia KP, et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol 2006;13:433–444.
  4. Simpson DM, Blitzer A, Brashear A, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidencebased review). Neurology 2008;70:1699–1706.
  5. Balash Y, Giladi N. Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. Eur J Neurol 2004;11:361–370.

SEE-ALSO